Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results.

Wyant T, Leach T, Sankoh S, Wang Y, Paolino J, Pasetti MF, Feagan BG, Parikh A.

Gut. 2015 Jan;64(1):77-83. doi: 10.1136/gutjnl-2014-307127. Epub 2014 Apr 24.


Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.

Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S.

Gastroenterology. 2014 Sep;147(3):618-627.e3. doi: 10.1053/j.gastro.2014.05.008. Epub 2014 May 21.


Immune response to hepatitis B vaccine with high antigen content in non-responders after standard primary vaccination in Chinese adults.

Pan HX, Zeng Y, Song XF, Zhang YJ, Xu K, Liang ZL, Zhu FC.

Vaccine. 2014 Jun 17;32(29):3706-12. doi: 10.1016/j.vaccine.2014.02.094. Epub 2014 Mar 27.


Vedolizumab as induction and maintenance therapy for Crohn's disease.

Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group.

N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739.


Targeting of gut specific leucocyte recruitment in IBD by vedolizumab.

Eksteen B.

Gut. 2015 Jan;64(1):8-10. doi: 10.1136/gutjnl-2014-307397. Epub 2014 Jun 19. No abstract available.


Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.

Betancourt AA, Delgado CA, Estévez ZC, Martínez JC, Ríos GV, Aureoles-Roselló SR, Zaldívar RA, Guzmán MA, Baile NF, Reyes PA, Ruano LO, Fernández AC, Lobaina-Matos Y, Fernández AD, Madrazo AI, Martínez MI, Baños ML, Alvarez NP, Baldo MD, Mestre RE, Pérez MV, Martínez ME, Escobar DA, Guanche MJ, Cáceres LM, Betancourt RS, Rando EH, Nieto GE, González VL, Rubido JC.

Int J Infect Dis. 2007 Sep;11(5):394-401. Epub 2007 Jan 24.


Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults.

Hernández-Bernal F, Aguilar-Betancourt A, Aljovin V, Arias G, Valenzuela C, de Alejo KP, Hernández K, Oquendo O, Figueredo N, Figueroa N, Musacchio A, Véliz G, García E, Mollineda AD, Juvier AI, Trujillo J, Delahanty A, Ortega D, Cinza Z, González VL.

Hum Vaccin. 2011 Oct;7(10):1026-36. doi: 10.4161/hv.7.10.15989. Epub 2011 Oct 1.


Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers.

Rosario M, Wyant T, Leach T, Sankoh S, Scholz C, Parikh A, Fox I, Feagan BG.

Clin Drug Investig. 2016 Nov;36(11):913-923.


Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group.

N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734.


Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.

Concha A, Giraldo A, Castañeda E, Martínez M, de la Hoz F, Rivas F, Depetris A, Svennerholm AM, Sack DA.

Bull Pan Am Health Organ. 1995 Dec;29(4):312-21.


Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination.

Young MD, Gooch WM 3rd, Zuckerman AJ, Du W, Dickson B, Maddrey WC.

J Med Virol. 2001 Jul;64(3):290-8.


Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype.

Milch C, Wyant T, Xu J, Parikh A, Kent W, Fox I, Berger J.

J Neuroimmunol. 2013 Nov 15;264(1-2):123-6. doi: 10.1016/j.jneuroim.2013.08.011. Epub 2013 Aug 31.


Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.

Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, Lang B, Ramael S, Moschetti V, Gruenenfelder F, Reilly P, Kreuzer J.

Lancet. 2015 Aug 15;386(9994):680-90. doi: 10.1016/S0140-6736(15)60732-2. Epub 2015 Jun 15.


Immune response to hepatitis B vaccination in HIV-positive adults with isolated antibodies to HBV core antigen.

Kaech C, Pache I, Bürgisser P, Elzi L, Darling KE, Cavassini M.

J Infect. 2012 Aug;65(2):157-64. doi: 10.1016/j.jinf.2012.03.009. Epub 2012 Mar 9.


Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab.

Moses J, Alkhouri N, Shannon A, Raig K, Lopez R, Danziger-Isakov L, Feldstein AE, Zein NN, Wyllie R, Carter-Kent C.

Am J Gastroenterol. 2012 Jan;107(1):133-8. doi: 10.1038/ajg.2011.295. Epub 2011 Aug 30.


Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.

Zanetti AR, Mariano A, Romanò L, D'Amelio R, Chironna M, Coppola RC, Cuccia M, Mangione R, Marrone F, Negrone FS, Parlato A, Zamparo E, Zotti C, Stroffolini T, Mele A; Study Group.

Lancet. 2005 Oct 15-21;366(9494):1379-84.


Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.

Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garcés-Sánchez M, Martinón-Torres F, Beeslaar J, Szenborn L, Wysocki J, Eiden J, Harris SL, Jones TR, Perez JL; 2001 Study Investigators.

Lancet Infect Dis. 2012 Aug;12(8):597-607. Epub 2012 May 7.


Supplemental Content

Support Center